A Hyderabad lab's low-cost artificial pancreas could reshape diabetes care

A team of researchers at IIT Hyderabad has unveiled an artificial pancreas system designed to automate insulin delivery for people with type 1 diabetes. Priced at roughly a tenth of imported alternatives, the device pairs a continuous glucose monitor with an algorithm-driven insulin pump. The development marks a significant step toward making closed-loop diabetes management accessible across low-income households.

The project reflects a growing wave of homegrown medical engineering across India. By sourcing components locally and simplifying the user interface, the researchers have produced a system that families can operate without extensive clinical training. Early trials conducted at partner hospitals in Telangana showed promising glycaemic control among adolescent participants.

Diabetes affects an estimated 101 million people in India, and the cost of imported insulin pumps often pushes automated care out of reach for many families. The Hyderabad team's approach could shift that calculus dramatically, especially in rural and semi-urban districts where specialist endocrinologists are scarce.

From bench to bedside: how the system was built

The IIT Hyderabad group spent three years iterating on a closed-loop algorithm that interprets glucose readings and adjusts basal insulin delivery every few minutes. The team deliberately avoided proprietary parts, instead using off-the-shelf sensors and a custom-built Android application. The pump mechanism draws from syringe-driver technology familiar to Indian biomedical engineers.

Crucially, the researchers published their hardware schematics openly, allowing other labs and even hospital workshops to replicate or modify the device. This open-source philosophy echoes the practical ingenuity seen in projects such as how a village in Himachal Pradesh used rainwater harvesting to end a drought cycle, where local resourcefulness solved a pressing community problem.

Clinical collaborators at the Government Hospital in Nizamabad helped refine the device through iterative testing. The team prioritised affordability over aesthetic refinement, recognising that families managing type 1 diabetes often face recurring monthly costs for consumables like insulin and test strips.

The engineering behind an affordable closed-loop system

At the heart of the device sits a proportional-integral-derivative controller, a feedback mechanism widely used in industrial automation. The controller weighs current and historical glucose values against target ranges, modulating insulin delivery in real time. This approach is simpler than the hybrid closed-loop systems marketed by global medtech firms. The team's lead engineer has described the algorithm as "deliberately conservative", erring on the side of safety.

The glucose sensor communicates with the smartphone app via Bluetooth, which then sends dosing commands to the pump. The app also generates alerts for hypoglycaemia and provides trend graphs that patients can share with their doctors during consultations. Engineers designed the system to function reliably even on older Android phones, a practical consideration given the prevalence of entry-level smartphones across South Asia.

Battery life was another focus area. The pump runs for up to seven days on a single charge, and the entire system can be stored without refrigeration, an important feature for households with inconsistent power supply.

Why this matters beyond Hyderabad

For people with type 1 diabetes in India, the daily burden of multiple insulin injections, finger-prick tests, and dietary vigilance can be overwhelming. An automated system that reduces decision fatigue has tangible quality-of-life benefits, particularly for working parents and school-aged children. The Hyderabad team hopes that state health schemes will eventually subsidise the device, making it available through public hospitals.

The innovation also has export potential. Several African and Southeast Asian countries face similar affordability barriers in diabetes care, and a low-cost artificial pancreas could find receptive markets in those regions. Discussions are reportedly underway with a Sri Lankan distributor for pilot deployment next year.

Local context for Australian readers

Australia has one of the highest rates of type 1 diabetes in the world, with the National Diabetes Services Scheme providing subsidised access to insulin pumps and continuous glucose monitors. Even with the NDSS and the Pharmaceutical Benefits Scheme covering a significant portion of costs, Australian families can still find themselves out of pocket by hundreds of dollars when upgrading to newer automated systems.

Research teams at the University of Melbourne and the Garvan Institute in Sydney have explored lower-cost alternatives, though their prototypes have generally focused on software rather than full hardware systems. The Hyderabad project offers a model that Australian biomedical engineers could study when designing devices for regional and Indigenous communities in the Northern Territory, where diabetes prevalence runs several times higher than the national average. Health authorities in Darwin and Cairns have flagged the need for culturally safe, affordable tools.

What comes next for accessible diabetes tech

Regulatory approval processes will determine how soon the device reaches patients. The researchers are compiling documentation for the Central Drugs Standard Control Organisation, while also seeking international certification to enable overseas distribution. Manufacturing partners in Pune are reportedly scaling up production of the pump housing.

If the system gains traction, it could pressure global manufacturers to reconsider pricing models. The real measure of success will be whether a family in Warangal or a young patient in Perth can soon obtain the device without financial hardship, and whether the children using it lead healthier, less interrupted lives.